



Regent Pacific Group Limited

(Incorporated in the Cayman Islands with Limited Liability)

Stock Code: 0575

18 April 2016

ANNOUNCEMENT


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

UPDATE ON COMMERCIALISATION OF PSD502[®]

SUBMISSION OF TYPE IB VARIATION FOR APPROVAL OF REDUCED FILL PRODUCT

Regent Pacific Group Limited (“**Regent Pacific**” or the “**Company**”, and collectively with its subsidiaries, the “**Group**”) is pleased to announce that it has received acceptable stability data for accelerated, intermediate and long term storage conditions from the first of three Good Manufacturing Practice batches of the reduced fill can (not less than 12 dose/can) that will support the Company in making a Type IB variation submission to the European Medicines Agency (“**EMA**”). The documentation is on track for submission to EMA by 20 April 2016, with the aim of receiving approval of the variation by 30 June 2016, such that the Company can obtain the variation payment of €6 million from Recordati S.p.A. (“**Recordati**”).

The Company will continue to work with Recordati for the successful commercial launch of PSD502[®], which is currently anticipated during the latter half of 2016. Under the terms of the Company’s licence agreement with Recordati, a payment of up to €10 million in total is payable upon first commercial sales of PSD502[®] in France, Germany, Italy, Spain and Portugal (being a payment of €2 million in respect of each of these countries).





Jamie Gibson, the Chief Executive Officer commented: “We are pleased with the positive results of the stability data allowing for the submission of the variation of the reduced fill can and the anticipated approval will represent the final step in the successful commercialisation of PSD502[®] in the European Union, Russia, Commonwealth of Independent States and certain countries of North Africa. The Company continues to focus on out-licensing in other major territories and on the submission for approval by the Food and Drug Administration within the USA. We look forward to giving updates to the market on both fronts in the near term.”

About PSD502[®] and Premature Ejaculation

PSD502[®] is a topical spray for the treatment of premature ejaculation containing lidocaine and prilocaine in a eutectic-like mixture. In two large, double blind, pivotal Phase III studies PSD502[®] showed a highly significant and clinically meaningful effect increasing mean intravaginal ejaculatory latency time at baseline from 0.5 minutes to 3.2 minutes. 87% of the patients in the studies were considered as responders with the product being well tolerated with no significant safety issues. PSD502[®] also showed positive effects across a wide range of other parameters including partner satisfaction.

Premature ejaculation is possibly the most common form of sexual dysfunction in men. Epidemiological studies conducted in the US and in Europe indicate a prevalence of 20% to 30% in men of all ages. There is currently no globally approved and effective pharmaceutical treatment for this condition.

The premature ejaculation market offers significant potential for development and growth given the absence of any widely approved pharmaceutical therapy with good patient acceptance. As a result, an effective drug therapy for premature ejaculation may have a commercial potential comparable to erectile dysfunction drugs.



About Regent Pacific

Regent Pacific is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare and life sciences sectors. Its wholly-owned subsidiary, Plethora Solutions Holdings Plc, is a specialty pharmaceutical company whose core product PSD502[®] is the first EU approved topical prescription treatment for Premature Ejaculation, set to launch in EU in the latter half of 2016. The Group has a strong track record of investments and has returned US\$298 million to shareholders in the 17.5 years of financial reporting since its Initial Public Offering.

On Behalf of the Board of
Regent Pacific Group Limited

Jamie Gibson
Director

Directors of the Company:

James Mellon (*Co-Chairman*)^{*}

Stephen Dattels (*Co-Chairman*)^{*}

Jamie Gibson (*Chief Executive Officer*)

David Comba[#]

Julie Oates[#]

Mark Searle[#]

Jayne Sutcliffe^{*}

^{*} *Non-Executive Directors*

[#] *Independent Non-Executive Directors*

Hong Kong, 18 April 2016